Suven Life receives five patents from four countries

The Hyderabad-based Suven Life Sciences Limited has received two product patents from Israel, and a patent each from Japan, China and New Zealand corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.These patents are valid through 2027, 2028, 2029 and 2030 respectively.
 
In a filing to the BSE on December 12, 2014, Suven Life said the patent includes the class of selective 5-HT compounds discovered by Suven.
 
These were being developed as therapeutic agents to be used in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's, attention deficiency hyperactivity disorder (ADHD), Huntington's, Parkinson and schizophrenia diseases.
 
FOR COMPLETE REPORT READ: Suven Life gets 5 new product patents